BrandMemo | manage and share brands you love  Pharmamedix su Facebook  Pharmamedix su Twitter
 Home | News | About us | Comitato scientifico | Iscriviti | Utenti | Etica | Contenuti | Guida | Faq | Stage | Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Paroxetina

Seroxat, Daparox, Sereupin e altri

Bibliografia - Quali fonti bibliografiche per Paroxetina?


         
  1. Abman S.H., Pediatr. Pulmonol. Suppl., 1999, 18, 201.

  2. Agenzia Italiana del Farmaco – AIFA, Comunicazione sull’Utilizzo degli antidepressivi, 2017, 16 maggio http://www.aifa.gov.it/content/comunicazione-sullutilizzo-degli-antidepressivi-16052017 (accesso: maggio 2017).

  3. AIFA – Agenzia Italiana del Farmaco, Nota Informativa 17 febbraio 2006, disponibile on line www.agenziafarmaco.it.

  4. Alwans et al., Clin. Mol. Teratol., 2005, 731, 291.

  5. Anderson B. et al., Epilepsy Res., 1991, 10, 201.

  6. Ansseau M. et al., Hum. Psychopharm., 1994, 9, 329.

  7. Baldwin D.S. et al., J. Clin. Psychiatry, 1996, 57 Suppl. 2, 46.

  8. Bannister S.J. et al., Acta Psychiatr. Scand., 1989, 80 (Suppl. 350), 102.

  9. Bayer A.J. et al., Acta Psychiatr. Scand., 1989, 80 Suppl. 350, 85.

  10. BMJ, 1999, 319, 1106.

  11. Casper R.C. et al., J. Pediatr., 2003, 142, 402.

  12. Centorrino F. et al., Am. J. Psychiatry, 1996, 153, 820.

  13. Chambers C.D. et al., NEJM, 2006, 354, 579.

  14. Claghorn J.L., Feighner J.P., J. Clin. Psychopharacol., 1993, 13 Suppl. 2, 23.

  15. Cooper S.M. et al., Acta Psychiatr. Scand., 1989, 80 Suppl. 350, 53.

  16. Dalhoff K. et al., Eur. J. Clin. Pharmacol., 1991, 41, 351.

  17. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.

  18. De Wilde J. et al., Hosp. Formul., 1993, 28, 36.

  19. Dechant K.L., Clissold S.P., Drugs, 1991, 41 (2), 225.

  20. Diav-Citrin O. et al., Teratology, 2002, 65, 298.

  21. Diav-Citrin O. et al., Br. J. Clin. Pharmacol., 2008, 66 (5), 695.

  22. Dorman T., Int. Clin. Psychopharmacol., 1992, 6 Suppl. 4, 53.

  23. Doyle G.D. et al., Acta Psychiatr. Scand., 1989, 80 Suppl. 350, 89.

  24. Dunbar G. et al., Eur. Neuropsychopharmacol., 1995, 5, 372.

  25. Ericson A. et al., Eur. J. Clin. Pharmacol., 1999, 55, 503.

  26. Eriksson E. et al., Neuropsychopharmacol., 1995, 12, 167.

  27. Fava M. et al., J. Clin. Psychiatry, 2000, 61, 863.

  28. Feighner J.P. et al., J. Affect. Disord., 1993, 28, 71.

  29. Finley P.R., Ann. Pharmacother., 1994, 28, 1359.

  30. Food and Drug Administration – FDA, Brisdelle – Prescribing information, 2017, aprile https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s005lbl.pdf (verificato: maggio 2017).

  31. Fukni H., Murai T., Clin. Neuropharmacol., 2002, 25 (5), 269.

  32. Gergel I. et al., Biol. Psychiatry, 1997, 42 (Suppl. 1), 26.

  33. Gilmor M.L. et al., Am. J. Psychiatry, 2002, 159, 1702.

  34. Goetz M.P., Loprinzi C.L., J. Natl. Cancer Inst., 2003, 95, 1734.

  35. Gooden K.M. et al., Curr. Drug Saf., 2015, 10 (2), 152.

  36. Gunasekara N.S. et al., Drugs, 1998, 55 (1), 85.

  37. Haddad P.M., Drug Saf., 2001, 24, 183/

  38. Haenen J. et al., Eur. J. Clin. Res., 1995, 7, 161.

  39. Hallberg P., Sjoblom V., J. Clin. Psychopharmacol., 2005, 25, 59.

  40. Hawley C.J. et al., Int. Clin. Psychopharmacol., 1997, 12, 13.

  41. Hawley C.J. et al., J. Psychopharmacol., 1994, 8 (4), 266.

  42. Hendrick V. et al., Am. J. Obstet. Gynecol., 2003, 188, 812.

  43. Kaye C.M. et al., Acta Psychiatr. Scand., 1989, 80 Suppl. 350, 60.

  44. Kallen B., Otterblad Olausson P., Reprod. Toxicol., 2003, 17, 255.

  45. Kallen B., Reprod. Toxicol., 2006, 21, 211.

  46. Kerr J.S. et al., Int. Clin. Psychopharmacol., 1992, 7, 101.

  47. Kiev A. Feiger A., J. Clin. Psychiatry, 1997, 58 (4), 146.

  48. Kulin N.A. et al., JAMA, 1998, 279, 609.

  49. J. Clin. Psychiatry, 2004, 65, 1696.

  50. John L. et al., Ann. Emerg. Med., 1997, 29, 287.

  51. Jureidini J.N. et al., BMJ, 2004, 328, 879.

  52. Laine K. et al., Arch. Gen. Psychiatry, 2003, 60, 720.

  53. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.

  54. Lecrubier Y., Judge R., Acta Psychiatr. Scand., 1997, 95, 153.

  55. Leyman S. et al., Eur. J. Clin. Res., 1995, 7, 287.

  56. Lydiard R.B. et al., Psychopharmacol. Bull., 1998, 34 (2), 175.

  57. Mason P.J. et al., Medicine, 2000, 79, 201.

  58. McClelland G.R. et al., Medicine, 1989, 80 (Suppl. 350), 50.

  59. Mills K.C., Critical Care Clinics, 1997, 13, 763.

  60. Moldovan Costei A. et al., Arch. Pediatr. Adolesc. Med., 2002, 156, 1129.

  61. Montgomery S.A., Dunbar G., Int. Clin. Psychopharmacol., 1993, 8 (3), 189.

  62. Montgomery S.A., Roberts A., Hum. Psychopharmacol., 1994, 9 Suppl. 1, 7.

  63. Moon C., Vince M., Br. J. Clin. Pract., 1996, 50, 240.

  64. Morag I. et al., J. Toxicol. Clin. 2004, 42, 97.

  65. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.

  66. NEJM, 2001, 344, 961.

  67. Nulman I. et al., Am. J. Psychiatry, 2002, 159, 1889.

  68. Oberlander T.F. et al., Pediatr. Res., 2002, 51, 443.

  69. Oehrberg S. et al., Br. J. Psychiatry, 1995, 167, 374.

  70. Ontiveros A., Garcia-Barriga, Br. J. Clin. Res., 1997, 8, 23.

  71. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.

  72. Orrico K.B. et al., Ann. Pharmacother., 2014, 48 (9), 1172.

  73. Oswald I., Adam K., Br. J. Clin. Pharmac., 1986, 22, 97.

  74. Patron C. ferrier I.N., BMJ, 2005, 334, 529.

  75. Prescrire Int., 2008, 17, 22.

  76. Reeves R.R., Bullen J.A., Psychosomatics, 1995, 36, 159.

  77. Rocca P. et al., Acta Psychiatr. Scand., 1997, 95, 444.

  78. Saletu B. et al., Sleep, 1991, 14, 439.

  79. Schone W., Ludwig M., J. Clin. Psychopharmacol., 1993, 13 Suppl. 2, 34.

  80. Seelen M. et al., Ann. Intern. Med., 1997, 126, 333.

  81. Serebruany V.L., Am. J. Med., 2006, 119, 113.

  82. Sharma T. et al., BMJ, 2016, 352, i65.

  83. Skop B.P. et al., Am. J. Emerg. Med., 1994, 12, 642.

  84. Staner L. et al., Sleep, 1995, 18, 470.

  85. Stearns V. et al., J. Natl. Cancer Inst., 2003, 95, 1758.

  86. Stearns V. et al., JAMA, 2003a, 289, 2827.

  87. Sundblad C. et al., Eur. Neuropsychopharmacoloy, 19977, 201.

  88. Szegedi A. et al., Pharmachopsychiatry, 1997, 30, 97.

  89. Taman L., Ozpoyraz N., Adv. Ther., 2002, 19, 17.

  90. Tatonetti N.P. et al., Clin. Pharmacol. Ther., 2011, 90 (1), 133.

  91. Tignol J., J. Clin. Psychopharmacol., 1993, 13 Suppl. 2, 18.

  92. Unfred C.L. et al., Organization of Teratology Information Services, 14 th Annual Meeting Program, 2001.

  93. van Walraven C. et al., BMJ, 2001, 323, 655.

  94. Vitiello B, Ordonez A.E., Expert. Opin. Pharmacother., 2016, 17 (17), 2273.

  95. Waksman et al., Clin. Toxicol., 2000, 38, 521.

  96. Warrington S.J. et al., Acta Psychiatr. Scand., 1989, 80 (Suppl. 350), 42.

  97. Zanardi R. et al., Am. J. Psychiatry, 1996, 153, 1631.

  98. Zeskind P.S., Stephens L.E., Pediatrics, 2004, 113, 368.

  99. Zeskind P.S. et al., Pediatr. Res., 2005, 57, 1624.

  100. Zohar J., Judge R., Br. J. Psychiatry, 1996, 169, 468.